The Patent Finder
GG

Gruenenthal GmbH

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

35 patents currently held

26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2027. from the record

Of the 26 now held by other companies, 18 name Adneuris Therapeutics Inc. as their current owner, and 8 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Mar 2027
Next term end
28
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 84 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Ends Sep 2027 · High confidence
Also notable
Cited by 45 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Aug 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 2, 2027
    The maintenance fee for Tamper Resistant and Dose-Dumping Resistant Pharmaceutical Dosage Form (US 10,335,373) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
  • 2 fees due Mar 3 to 15, 2027 · next Mar 3
  • 2 fees due Apr 6 to 20, 2027 · next Apr 6
  • 1 fee due Oct 21, 2027
    The maintenance fee for Substituted Pyrrolidine Amides I (US 10,626,106) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
  • 1 fee due Nov 14, 2027
    The maintenance fee for Further Substituted Triazolo Quinoxaline Derivatives (US 11,981,677) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 28 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,718,640Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels
In force
 · High confidence
In forceHigh confidence
US 8,338,395Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels
In force
 · High confidence
In forceHigh confidence
US 11,739,049Process for the Preparation of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-PROPYL)-PHENOL
In force
 · High confidence
In forceHigh confidence
US 8,939,748Method for the Production of a Form of Administration of a Medicament
In force
 · High confidence
In forceHigh confidence
US 8,088,322Method and Device for Ultrasound-Pressing a Tablet or a Multiparticulate Medicament
In force
 · High confidence
In forceHigh confidence
US 8,263,809Preparation of 3-[(1R,2R)-3-(DIMETHYLAMINO)-1ETHYL-2-Methylpropyl]PHENOL
In force
 · High confidence
In forceHigh confidence
US 8,383,152Pharmaceutical Dosage Form
In force
 · High confidence
In forceHigh confidence
US 8,134,032Crystalline Modifications of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-PROPYL)-PHENOL
In force
 · High confidence
In forceHigh confidence
US 8,877,974Process for the Preparation of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-PHENOL
Grace period ended
 · Low confidence
Grace period endedLow confidence
US 9,579,285Preparation of a Powdery Pharmaceutical Composition by Means of an Extruder
In force
 · High confidence
In forceHigh confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
Also on record, not counted in the 35: 26 patents in force now held by others · 250 patents ended · 11 applications pending · 231 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited